{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:51:41Z","timestamp":1774497101413,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005192","name":"Danmarks Tekniske Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001825","name":"Danish Agency for Science and Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.ejpb.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T16:07:23Z","timestamp":1441469243000},"page":"329-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement"],"prefix":"10.1016","volume":"96","author":[{"given":"Sofie","family":"Trier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Linderoth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Bjerregaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger M.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik L.","family":"Rahbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.09.001_b0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj3120725","article-title":"Albumin binding of insulins acylated","volume":"312","author":"Kurtzhals","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejpb.2015.09.001_b0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1248\/bpb.25.29","article-title":"N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells","volume":"25","author":"Dasgupta","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2015.09.001_b0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11095-004-1189-z","article-title":"Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide","volume":"22","author":"Yuan","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.09.001_b0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1073\/pnas.93.1.427","article-title":"Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide","volume":"93","author":"Gozes","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.09.001_b0025","article-title":"Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake","author":"Dalb\u00f8ge","year":"2014","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.ejpb.2015.09.001_b0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0168-3659(03)00008-7","article-title":"Reversible lipidization for the oral delivery of salmon calcitonin","volume":"88","author":"Wang","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.09.001_b0035","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.09.001_b0040","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.2174\/092986712799945003","article-title":"Converting peptides into drug leads by lipidation","volume":"19","author":"Zhang","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.09.001_b0045","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"Madsen","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2015.09.001_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0378-5173(00)00489-0","article-title":"Gastric retention and stability of lipidized Bowman\u2013Birk protease inhibitor in mice","volume":"204","author":"Wang","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.09.001_b0055","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2015.09.001_b0060","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2015.09.001_b0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.09.001_b0070","doi-asserted-by":"crossref","DOI":"10.1023\/A:1007644706286","article-title":"Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characteristics of DADLE derivatives in rats","volume":"17","author":"Uchiyama","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.09.001_b0075","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0378-5173(80)90117-9","article-title":"The temperature dependence and thermodynamics of partitioning of phenols in the n-octanol-water system","volume":"6","author":"Rogers","year":"1980","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.09.001_b0080","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1023\/A:1018882221008","article-title":"Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption","volume":"16","author":"Balon","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.09.001_b0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1461-5347(99)00188-1","article-title":"Absorption prediction from physicochemical parameters","volume":"2","author":"Kr\u00e4mer","year":"1999","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.ejpb.2015.09.001_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/193381a0","article-title":"Calcitonin-a hormone from the parathyroid which lowers the calcium-level of the blood","volume":"193","author":"Copp","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2015.09.001_b0095","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/10606820213681","article-title":"Molecular pharmacology of the calcitonin receptor","volume":"8","author":"Purdue","year":"2002","journal-title":"Recept. Channels"},{"key":"10.1016\/j.ejpb.2015.09.001_b0100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0091270010372625","article-title":"Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials","volume":"51","author":"Karsdal","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2015.09.001_b0105","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1016\/S0021-9258(18)53268-3","article-title":"The structure and mechanism of formation of human calcitonin fibrils","volume":"268","author":"Arvinte","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2015.09.001_b0110","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jps.2600840610","article-title":"Enhanced potency of human calcitonin when fibrillation is avoided","volume":"84","author":"Cudd","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.09.001_b0115","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ejps.2013.01.009","article-title":"Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer","volume":"48","author":"Petersen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.09.001_b0120","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial","volume":"27","author":"Binkley","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejpb.2015.09.001_b0125","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jconrel.2013.09.004","article-title":"Mucoadhesive intestinal devices for oral delivery of salmon calcitonin","volume":"172","author":"Gupta","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.09.001_b0130","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jps.10573","article-title":"Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin","volume":"93","author":"Sang Yoo","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.09.001_b0135","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2005.05.016","article-title":"Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts","volume":"106","author":"Song","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.09.001_b0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2008.11.013","article-title":"Chitosan\u2013aprotinin coated liposomes for oral peptide delivery: development, characterisation and in vivo evaluation","volume":"370","author":"Werle","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.09.001_b0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11095-006-9128-9","article-title":"Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity","volume":"24","author":"Cheng","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.09.001_b0150","article-title":"Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin","volume":"88","author":"Cheng","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.09.001_b0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jconrel.2006.06.007","article-title":"Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy","volume":"114","author":"Youn","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2015.09.001_b0160","doi-asserted-by":"crossref","first-page":"e109939","DOI":"10.1371\/journal.pone.0109939","article-title":"Acylation of Glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability","volume":"9","author":"Trier","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2015.09.001_b0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0021-9673(92)85087-A","article-title":"Nitrogen-specific liquid chromatography detector based on chemiluminescence: application to the analysis of ammonium nitrogen in waste water","volume":"592","author":"Fujinari","year":"1992","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.ejpb.2015.09.001_b0170","doi-asserted-by":"crossref","first-page":"9277","DOI":"10.3390\/ijms12129277","article-title":"The slowly aggregating salmon Calcitonin: a useful tool for the study of the amyloid oligomers structure and activity","volume":"12","author":"Diociaiuti","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2015.09.001_b0175","first-page":"183","article-title":"Intraluminal pH of the human gastrointestinal tract","volume":"46","author":"Fallingborg","year":"1999","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.ejpb.2015.09.001_b0180","series-title":"Oral Deliv. Macromol. Drugs","first-page":"49","article-title":"The absorption barrier","author":"Borchard","year":"2009"},{"key":"10.1016\/j.ejpb.2015.09.001_b0185","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1146\/annurev.anchem.1.031207.112747","article-title":"Liposomes: technologies and analytical applications","volume":"1","author":"Jesorka","year":"2008","journal-title":"Annu. Rev. Anal. Chem."},{"key":"10.1016\/j.ejpb.2015.09.001_b0190","doi-asserted-by":"crossref","first-page":"24193","DOI":"10.1074\/jbc.M603528200","article-title":"Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix","volume":"281","author":"Andreotti","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2015.09.001_b0195","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J","article-title":"Intestinal permeation enhancers","volume":"89","author":"Aungst","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.09.001_b0200","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s11095-007-9488-9","article-title":"Safe and effective permeation enhancers for oral drug delivery","volume":"25","author":"Whitehead","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.09.001_b0205","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bpj.2010.11.040","article-title":"Selective acylation enhances membrane charge sensitivity of the antimicrobial peptide mastoparan-x","volume":"100","author":"Etzerodt","year":"2011","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejpb.2015.09.001_b0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bpj.2011.05.047","article-title":"Thermodynamic profiling of peptide membrane interactions by isothermal titration calorimetry: a search for pores and micelles","volume":"101","author":"Henriksen","year":"2011","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejpb.2015.09.001_b0215","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1039\/c2sm25075f","article-title":"A GALA lipopeptide mediates pH- and membrane charge dependent fusion with stable giant unilamellar vesicles","volume":"8","author":"Etzerodt","year":"2012","journal-title":"Soft Matter"},{"key":"10.1016\/j.ejpb.2015.09.001_b0220","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.09.001_b0225","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1529\/biophysj.105.079475","article-title":"Calcitonin forms oligomeric pore-like structures in lipid membranes","volume":"91","author":"Diociaiuti","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejpb.2015.09.001_b0230","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.bbamem.2008.09.016","article-title":"Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery","volume":"1788","author":"Deli","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2015.09.001_b0235","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.2042-7158.1998.tb03319.x","article-title":"Cytotoxicity of absorption enhancers in Caco-2 cell monolayers","volume":"50","author":"Sakai","year":"1998","journal-title":"J. Pharm. Pharmacol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115003689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115003689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:24:37Z","timestamp":1656937477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115003689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":47,"alternative-id":["S0939641115003689"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.09.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acylation of salmon calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}